UVM Larner College of Medicine Department of MMG
Welcome,         Profile    Billing    Logout  
 1 Trial 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lutton, Patricia
NCT05048875: An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

Completed
2
56
US
Cohort 1 - Group 1 JNJ High Dose, JNJ-64281802 (Sentinel high dose), Cohort 1 - Group 2 JNJ Medium Dose, JNJ-64281802 (medium dose), Cohort 1 - Group 2 JNJ Low Dose, JNJ-64281802 (low dose), Cohort 1 - Group 1/2 Placebo, Placebo High Dose
National Institute of Allergy and Infectious Diseases (NIAID), Janssen, LP, National Institutes of Health (NIH)
Dengue
05/23
09/24
AV1-PPD-0006, NCT06799741: A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

Recruiting
2
84
US
AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo
AbViro LLC
DENV-3 Controlled Human Infection Model
10/25
10/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lutton, Patricia
NCT05048875: An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

Completed
2
56
US
Cohort 1 - Group 1 JNJ High Dose, JNJ-64281802 (Sentinel high dose), Cohort 1 - Group 2 JNJ Medium Dose, JNJ-64281802 (medium dose), Cohort 1 - Group 2 JNJ Low Dose, JNJ-64281802 (low dose), Cohort 1 - Group 1/2 Placebo, Placebo High Dose
National Institute of Allergy and Infectious Diseases (NIAID), Janssen, LP, National Institutes of Health (NIH)
Dengue
05/23
09/24
AV1-PPD-0006, NCT06799741: A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

Recruiting
2
84
US
AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo
AbViro LLC
DENV-3 Controlled Human Infection Model
10/25
10/25

Download Options